Author

Yaqian Han

Observed names: Ya-Qian Han, Ya-qian Han, Ya‐Qian Han

Observed institutions: Central South University, Henan University, University of Toronto, Zhengzhou University, Hunan Cancer Hospital, Henan Provincial People's Hospital

ORCID: 0009-0005-7733-3799

Observed ORCID: 0009-0005-7733-3799

OpenAlex ID: A5100737928

Exosomal miRNAs in tumor microenvironment

2020 · Shiming Tan, Longzheng Xia, et al. · Journal of Experimental & Clinical Cancer Research · 220

PDF

BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study

2024 · Yuxiang Ma, Yan Huang, et al. · The Lancet Oncology · 179

Refining the 8th edition TNM classification for EBV related nasopharyngeal carcinoma

2024 · Xiao-Jing Du, Gao-Yuan Wang, et al. · Cancer Cell · 83

PET/CT-guided dose-painting versus CT-based intensity modulated radiation therapy in locoregional advanced nasopharyngeal carcinoma

2017 · Feng Liu, Xu-ping Xi, et al. · Radiation Oncology · 41

PDF

Diffusion-Weighted Magnetic Resonance Imaging-Guided Dose Painting in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Treated With Induction Chemotherapy Plus Concurrent Chemoradiotherapy: A Randomized, Controlled Clinical Trial

2022 · Shengnan Fu, Yanxian Li, et al. · International Journal of Radiation Oncology*Biology*Physics · 38

MiRNAs in Radiotherapy Resistance of Nasopharyngeal Carcinoma

2020 · Yutong Tian, Lu Tang, et al. · Journal of Cancer · 38

PDF

High flow nasal cannula for patients undergoing bronchoscopy and gastrointestinal endoscopy: A systematic review and meta-analysis

2022 · Yuan Tao, Mingyang Sun, et al. · Frontiers in Surgery · 36

Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China

2025 · Yunpeng Yang, Huaqiang Zhou, et al. · The Lancet · 35

The role of tripartite motif-containing 28 in cancer progression and its therapeutic potentials

2023 · Yiqing Yang, Shiming Tan, et al. · Frontiers in Oncology · 26

PDF

Effects of Cognitive Behavioral Therapy for Depression and Anxiety, Response Rates and Adverse Events in Patients with Locoregional Advanced Nasopharyngeal Carcinoma

2021 · Feng Liu, Sheng-nan Fu, et al. · Integrative Cancer Therapies · 14

Advanced image-identified extranodal extension of retropharyngeal lymph nodes in the refinement of N classification for nasopharyngeal carcinoma

2025 · Wei Jiang, Gao-Yuan Wang, et al. · Cell Reports Medicine · 9

Distribution of regional lymph nodes metastasis in 870 cases of nasopharyngeal carcinoma and the suggestions for individualized elective prophylactic neck irradiation with intensity‐modulated radiotherapy

2023 · Lei Wang, Zheng Wu, et al. · Cancer Medicine · 8

PDF

Radiation-induced rhinosinusitis in patients with nasopharyngeal carcinoma

2025 · Si-Yuan Chen, Xiao-Tong Duan, et al. · Radiotherapy and Oncology · 7

Prognostic Value of Survivin in Nasopharyngeal Carcinoma: A Systematic Review and Meta-analysis

2021 · Wenji Xie, Ouying Yan, et al. · Journal of Cancer · 7

PDF

Subsequent Survival and Loss of Lifetime for Patients With Progression‐Free 24 Months After Treatment in Nasopharyngeal Carcinoma: A Comprehensive Nationwide Population‐Based Analysis

2025 · Yang Liu, Yaqian Han, et al. · MedComm · 6

Prognostic Relevance of 18F-FDG-PET/CT-Guided Target Volume Delineation in Loco-Regionally Advanced Nasopharyngeal Carcinomas: A Comparative Study

2021 · Ouying Yan, Hui Wang, et al. · Frontiers in Oncology · 5

PDF

Long-term outcomes of anlotinib and penpulimab combined with chemotherapy in the treatment of patients with metastatic nasopharyngeal carcinoma that failed definitive platinum-based chemoradiotherapy.

2024 · Shuang Huang, Xiaozhong Chen, et al. · Journal of Clinical Oncology · 3

PDF

A randomized phase II trial of diffusion-weighted MR imaging-guided radiotherapy plus chemotherapy versus standard chemoradiotherapy in locoregional advanced nasopharyngeal carcinoma.

2021 · Feng Liu, Shengnan Fu, et al. · Journal of Clinical Oncology · 3

Case report: Successful treatment of advanced urothelial carcinoma with trophoblastic differentiation using Tislelizumab and Disitamab vedotin

2024 · Yaqian Han, Yujuan Zhou, et al. · Heliyon · 2

Chemotherapy combined with anlotinib, toripalimab and stereotactic radiotherapy in oligo-metastatic nasopharyngeal carcinoma: A prospective, multicenter phase II clinical study.

2023 · Dong Yang, Xueying Hu, et al. · Journal of Clinical Oncology · 1

Occult lymph node metastasis in cN0 tongue squamous cell carcinoma: A prospective observational study.

2023 · Sanqian Huang, Feiping Li, et al. · Journal of Clinical Oncology · 1

Imaging-detected extranodal extension grading and T-category adjustment to refine the TNM-9 classification for nasopharyngeal carcinoma

2026 · Min-Yu Wen, Guan-Jie Qin, et al. · Med

Curative-intent management of de novo metastatic nasopharyngeal carcinoma: an evidence-based consensus guideline from the International Collaborating Oncology Organisations

2026 · Qiao-Juan Guo, Qin Liu, et al. · The Lancet Oncology

A Phase 1 study of subcutaneous toripalimab in recurrent or metastatic nasopharyngeal carcinoma

2026 · Hai‐Qiang Mai, Ya‐Qian Han, et al. · British Journal of Clinical Pharmacology

Penpulimab and Gemcitabine With or Without Anlotinib in Metastatic Nasopharyngeal Carcinoma: A Randomized, Open‐Label, Multicenter Phase 2 Study

2026 · Shuang Huang, Ya‐Qian Han, et al. · International Journal of Cancer

PDF

Works count: 32

Citation count: 762

H-index: 10

I10-index: 10